Cancer patients whose tumors carry mutations in DNA repair genes beyond the well-known BRCA1/2 may benefit from PARP inhibitor therapy previously reserved for hereditary breast and ovarian cancers. This precision medicine approach could expand treatment options for thousands of patients with treatment-resistant tumors who currently have limited therapeutic choices.
The Drug Rediscovery Protocol tested olaparib in 49 patients whose cancers harbored defective copies of various homologous recombination repair genes. Clinical benefit occurred in 32% of patients with ATM gene alterations, primarily in prostate cancers, and 42% of those with other repair gene defects including CDK12 and RAD51B mutations. Median progression-free survival reached 3.4-3.5 months across both groups, with overall survival extending to 8-9 months. Notably, CDK12-altered tumors showed particular responsiveness, while PPP2R2A mutations conferred no benefit.
This targeted approach represents a significant evolution in PARP inhibitor application. While olaparib gained initial approval for BRCA-mutated cancers based on their characteristic DNA repair deficiency, this study validates the broader concept of synthetic lethality across multiple repair pathway components. The findings align with emerging understanding that various genes within the homologous recombination network create similar therapeutic vulnerabilities when disrupted. However, the modest survival improvements and variable responses across different gene alterations underscore the complexity of predicting drug sensitivity based solely on pathway membership. The work supports expanding genomic testing to identify actionable mutations beyond traditional biomarkers, though larger studies will be needed to establish definitive clinical utility for each specific gene alteration.